Johnson & Johnson drops RSV vaccine program
Mar. 29, 2023 9:25 AM ETJohnson & Johnson (JNJ)GSK, PFEBy: Dulan Lokuwithana, SA News Editor8 Comments
Michael Vi
- Janssen unit of Johnson & Johnson (NYSE:JNJ) announced Wednesday that the company would exit its adult respiratory syncytial virus (RSV) vaccine program and will discontinue its Phase 3 EVERGREEN study.
- The EVERGREEN study, started in 2021, was a randomized and placebo-controlled trial to evaluate the company's RSV vaccine candidate in over 27,000 adults aged 60 years and above.
- The decision comes after a portfolio review and an assessment of the current RSV vaccine landscape, Janssen said.
- "The decision to discontinue the Company's RSV adult vaccine program is part of a broader effort to make strategic choices for its pipeline and research and development (R&D) investments to focus on medicines with the greatest potential benefit to patients," the company explained.
- JNJ's exit comes as Pfizer (PFE) and GSK (GSK) await FDA decisions on their marketing application for RSV vaccines Abrysvo and Arexvy, respectively, by May 2023.